IFNA1 and systemic lupus erythematosus: Recent research has indicated that HCQ has the potential to inhibit early mediators such as the B cell activating factor (BAFF) and interferon (IFN), hence reducing the levels of IFN‐γ‐induced protein 10 (IP‐10) in individuals with partial or new‐onset SLE [7].